American Journal of Cardiology
Volume 105, Issue 4 , Pages 445-452 , 15 February 2010

Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)

  • Christopher P. Cannon, MD

      Affiliations

    • TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: (617) 278-0146; fax: (617) 734-7329
    • ,
  • Karen E. Rhee, MD

      Affiliations

    • Miriam Hospital, Providence, Rhode Island
    • ,
  • Robert M. Califf, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • William E. Boden, MD

      Affiliations

    • Buffalo General Hospital and State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York
    • ,
  • Alan T. Hirsch, MD

      Affiliations

    • University of Minnesota School of Public Health and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
    • ,
  • Mark J. Alberts, MD

      Affiliations

    • Northwestern University Medical School, Chicago, Illinois
    • ,
  • Greg Cable, PhD, MPA

      Affiliations

    • Department of Biostatistics, sanofi-aventis, Bridgewater, New Jersey
    • ,
  • Mingyuan Shao, MS

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
    • ,
  • E. Magnus Ohman, MD

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • P. Gabriel Steg, MD

      Affiliations

    • INSERM U698 Université Paris 7 AP-HP, Paris, France
    • ,
  • Kim A. Eagle, MD

      Affiliations

    • Cardiovascular Center, University of Michigan, Ann Arbor, Michigan
    • ,
  • Deepak L. Bhatt, MD, MPH

      Affiliations

    • Veterans Affairs Boston Healthcare System and Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • REACH Registry Investigators

Received 12 June 2009 ,Revised 7 October 2009 ,Accepted 7 October 2009.

References 

  1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  2. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218–1222
  3. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363–2372
  4. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189
  5. Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206
  6. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151:786.e1–786.e10
  7. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147:W163–W194
  8. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203–212
  9. Algra A, De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev. 2006;3:CD001342
  10. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–227
  11. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–974
  12. Manzano-Fernández S, Pastor FJ, Marín F, Cambronero F, Caro C, Pascual-Figal DA, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest. 2008;134:559–567
  13. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860
  14. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:405–410
  15. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840
  16. Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, Pell ACH, Sandercock PAG, Fox KAA, Lowe GDO, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis. Presented at the European Society of Cardiology, Barcelona, Spain, 2009.
  17. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–2141
  18. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301:1909–1919

 The REduction of Atherothrombosis for Continued Health (REACH) Registry, statistical support, and editorial assistance were supported by the Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership, New York, New York. The REACH Registry has been endorsed by the World Heart Federation, Geneva, Switzerland.

PII: S0002-9149(09)02519-3

doi: 10.1016/j.amjcard.2009.10.014

American Journal of Cardiology
Volume 105, Issue 4 , Pages 445-452 , 15 February 2010

Article Tools

* Image Usage & Resolution